Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in < em > EGFR < /em > -Mutant Lung Cancer
CONCLUSIONS: Phosphoproteomic analysis may help elucidate the mechanisms of resistance to molecular-targeted therapies in lung cancer. Mutual phosphorylation of FAK and Src is involved in osimertinib resistance. Thus, FAK and Src inhibition may be novel treatment strategies for osimertinib-resistant NSCLC.PMID:38646155 | PMC:PMC11031815 | DOI:10.1016/j.jtocrr.2024.100668 (Source: Cell Research)
Source: Cell Research - April 22, 2024 Category: Cytology Authors: Takehiro Tozuka Rintaro Noro Keisuke Yoshida Satoshi Takahashi Mariko Hirao Kuniko Matsuda Yasuhiro Kato Shinji Nakamichi Susumu Takeuchi Masaru Matsumoto Akihiko Miyanaga Shinobu Kunugi Kazufumi Honda Jun Adachi Masahiro Seike Source Type: research
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma
In this study, we tested a novel approach of "repurposing" a biomarker typically associated with breast cancer for use in melanoma. HER2/neu is a well characterized biomarker in breast cancer for which effective anti-HER2/neu therapies are readily available. We constructed a lentivirus encoding c-erb-B2 (the animal homolog to HER2/neu). This was used to transfect B16 melanoma in vitro for use in an orthotopic preclinical mouse model, which resulted in expression of c-erb-B2 as a neoantigen target for anti-c-erb-B2 monoclonal antibody (7.16.4). The c-erb-B2-expressing melanoma was designated B16/neu. 7.16.4 produced statist...
Source: Cell Research - April 22, 2024 Category: Cytology Authors: Emmanuel M Gabriel Brian Necela Deborah Bahr Sneha Vivekanandhan Barath Shreeder Sanjay Bagaria Keith L Knutson Source Type: research
Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price
CONCLUSIONS: The BTD expedites patient access to effective and innovative, but also expensive, new cancer drugs and indications.PMID:38648855 | DOI:10.6004/jnccn.2023.7110 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 22, 2024 Category: Cancer & Oncology Authors: Daniel Tobias Michaeli Thomas Michaeli Source Type: research
Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model
CONCLUSIONS: Policy discussions about the evaluation of AAP cannot be complete without assessing its impact on its most important target outcome: patient survival. To date, there has been no estimation of the life year gain delivered by the AAP. Our research shows that substantial number of life years were gained for patients with high unmet need by the cancer therapies approved through the program.PMID:38648848 | DOI:10.6004/jnccn.2024.7010 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 22, 2024 Category: Cancer & Oncology Authors: Ágnes Benedict G ábor Szabó Kinga Marczell Bridget Doherty Silas Martin Source Type: research
Health Care Lobbying and Oncology
CONCLUSIONS: Although overall health sector lobbying has increased, physician/health professional lobbying has remained relatively stable in recent years, spending for lobbying by OPPOs has increased. Continued efforts to understand the utility and value of lobbying in health care and across oncology are needed as the costs of care continue to increase.PMID:38648846 | DOI:10.6004/jnccn.2023.7120 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - April 22, 2024 Category: Cancer & Oncology Authors: Nirmal Choradia Aaron Mitchell Ryan Nipp Source Type: research
